Real-time algorithmic exchange and processing of pharmaceutical quality data and information
Related Experiment Video
Updated: Jul 18, 2025

Generation of Dynamical Environmental Conditions using a High-Throughput Microfluidic Device
Published on: April 17, 2021
Craig Anderson1, Marquerita Algorri2, Michael J Abernathy2
1Department of Global Regulatory Science - International Labeling Group, Pfizer Inc., Kirkland, Quebec H9J 2M5, Canada.
Abstract:
Herein, a modern method is proposed for exchanging and processing real-time medicinal product information using Health Level 7 International's (HL7) Fast Healthcare Interoperability Resources (FHIR®) standard, Application Programming Interfaces (API), digitization and artificial intelligence. FHIR is presently in use largely to facilitate interactions between patient-facing healthcare institutions, such as hospitals, doctor's offices, and laboratories, for electronic health record management and exchange. There are several ongoing efforts to adapt the FHIR standard for regulatory use cases to support the needs of the global biopharmaceutical industry, including the exchange of Electronic Product Information (ePI); chemistry, manufacturing, and controls (CMC) data; and adverse event reporting. Once in place, this new method of data exchange is expected to (1) improve efficiency by reducing the time and effort needed to manage regulatory information; (2) accelerate decision making; (3) encourage innovation in pharmaceutical manufacturing; (4) improve the ability and agility of information exchange. Currently, the end-to-end timescale for the pharmaceutical regulatory workflow is measured in months and years. This new paradigm will use FHIR APIs and other supporting technologies to reduce the potential time for data exchange from months to days, hours, minutes, and eventually sub-seconds. With such drastic improvements in speed provided by digitization, automation, and interoperability, the biopharmaceutical industry can reach more patients, and more quickly than at any time in the industry's 100+ year history. The present work will focus on examining specific real-world implementation examples for using FHIR to support exchange of CMC information within and across the biopharmaceutical industry.
Related Concept Videos
Bioequivalence: Overview
Analysis of Population Pharmacokinetic Data
Issues And Trends In Healthcare Delivery System
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...

